Global report - April 21, 2016
Johannesburg joins Cities Changing Diabetes
The city of Johannesburg joins Novo Nordisk’s Cities Changing Diabetes programme and becomes the first African city to join the global initiative. The addition of the largest city in South Africa as a partner city means Cities Changing Diabetes now brings together six cities across four continents in the fight against urban diabetes. “Diabetes is […]
Clinical Trials - April 14, 2016
Positive results for Novo Nordisk’s Saxenda
Novo Nordisk’s Saxenda demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo. New data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016). The three-year part of […]
Pharma Business - February 8, 2016
Novo Nordisk increased operating profit
Novo Nordisk increased operating profit by 43% in 2015 to DKK 49,4 billion and the company achieved its four long-term financial targets established in January 2013. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, the operating margin was 43.6% corresponding to an increase in operating profit in local […]
Pharma Business - January 12, 2016
Novo Nordisk files for regulatory approval of long-acting factor IX
Novo Nordisk today announced the submission to the European Medicines Agency of the Marketing Authorisation Application for the approval of long-acting factor IX, nonacog beta pegol. Nonacog beta pegol is a glycopegylated recombinant factor IX with a significantly improved pharmacokinetic (PK) profile, developed for patients with haemophilia B. Novo Nordisk expects to file the Biologics […]
Collaboration - January 5, 2016
Novo Nordisk enter partnership to improve environment and health
Novo Nordisk and the C40 Cities Climate Leadership Group (C40) have entered a research-based partnership aimed at establishing that green policies in cities are beneficial to both the state of the environment and the health of their citizens. The collaboration aims to generate new insights on a range of co-benefits of climate action, in particular the health […]
Clinical Trials - December 21, 2015
Promising results from Novo Nordisk
Novo Nordisk has filed for regulatory approval of faster-acting insulin aspart for the treatment of type 1 and 2 diabetes in the EU and the US. Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes […]
